Author

Paul Wanek

RWTH Aachen University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

Marcelo AS de ToledoiD· 2 shared Steffen KoschmiederiD· 2 shared Susanne Schmitz· 2 shared Adam BenabidiD· 1 shared Aleksandar V. Kargaliev· 1 shared Alessia PiergentiliiD· 1 shared Alexandru FloreaiD· 1 shared Anna Bock· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Marcelo AS de ToledoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

PDE3A-SLFN12 Molecular Glues Target Multiple KIT D816V Cell Types in Preclinical Models of Mast Cell Malignancies

Xuhuang Fu, Anne Kaiser, Payal Chawla, Axel Choidas, Peter Habenberger, Tiago Maié, Alessia Piergentili, Venkatakrishnan Harihara, Paul Wanek, Susanne Schmitz, Maximilian Ackermann, Deborah Christen, Jens Panse, Hubert Schorle, Michel Arock, , Martin Zenke

This paper identifies PDE3A-SLFN12 molecular glues as a novel therapeutic target for KIT D816V-driven mast cell malignancies, showing their efficacy in killing multiple KIT D816V cell types and synergy with tyrosine kinase inhibitors.

bioRxiv · Aug 18, 2026 · PreprintCancer Biology

Oncodevelopmental plasticity of the skeleton in myeloid neoplasms

Salim Atakhanov, Ian Ghezzi, Hector Tejeda Mora, Lucas Greven, Marta Rizk, Lina Schmidt, Katrin Goetz, Lina Merg, Valeria Solozobova, Adam Benabid, Pia Wanner, Niklas Lutterbach, Aleksandar V. Kargaliev, Mathias Schäfersküpper, Alexandru Florea, , Rebekka K. Schneider

This study identifies a novel mechanism in myelofibrosis where a single mutation drives both bone formation and resorption, revealing THBS1 as a therapeutic target.

bioRxiv · Mar 21, 2026 · PreprintCancer Biology